share_log

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

信誠在明與艾伯維公司宣佈合作開發一種新型三特異性抗體候選藥物用於多發性骨髓瘤
PR Newswire ·  01/13 14:05

SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both China and the U.S.

上海和北芝加哥,伊利諾伊州,2025年1月13日 /PRNewswire/ -- 心切在大中華區(香港交易所:2096)和艾伯維公司(紐交所:ABBV)今天宣佈了一項許可協議的選擇,以開發SIM0500,一種正在調查的新藥候選。SIM0500目前正在中國和美國進行一期臨牀試驗,針對復發或難治性多發性骨髓瘤(MM)患者。

Cooperation of Simcere Zaiming and Abbvie
心切與艾伯維的合作

SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a low affinity/high target-activating CD3 engaging arm and binding sites for the two tumor antigens: G-Protein-coupled receptor class 5 member D (GPRC5D) and B-cell maturation antigen (BCMA). SIM0500 has shown strong T cell cytotoxicity against multiple myeloma (MM) cells by leveraging a combination of various antitumor effects.

SIM0500是一種人源化的三特異性抗體,靶向GPRC5D、BCMA和CD3,由心切獨立開發,使用他們的T細胞接合多特異性抗體科技平台。該分子具有低親和力/高靶向激活的CD3接合臂和用於兩種腫瘤抗原的結合位點:G-蛋白偶聯受體5類成員D(GPRC5D)和B細胞成熟抗原(BCMA)。SIM0500通過利用各種抗腫瘤效應的組合,顯示出了對多發性骨髓瘤(MM)細胞的強T細胞細胞毒性。

"As a leader in hematologic malignancies, AbbVie is committed to advancing innovative treatments for complex cancers like multiple myeloma through our relentless R&D efforts and collaborations," said Mariana Cota Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. "We look forward to partnering with Simcere Zaiming, to advance this novel trispecific antibody, which has the potential to help address significant unmet medical needs for people living with multiple myeloma"

"作爲血液惡性腫瘤的領導者,艾伯維致力於通過我們不懈的研發努力和合作,推動複雜癌症(如多發性骨髓瘤)的創新治療,"艾伯維血液學治療領域副總裁,醫學博士Mariana Cota Stirner說。"我們期待與心切合作,推動這一新型三特異性抗體的發展,這有助於解決多發性骨髓瘤患者尚未滿足的重大醫療需求。"

"SIM0500 is developed via Simcere Zaiming's proprietary T-cell engager platform," said Renhong Tang, PhD, CEO of Simcere Zaiming. "We are excited to partner with AbbVie on this novel drug candidate and look forward to working together to advance the clinical development of SIM0500. "

"SIM0500是通過心切獨有的T細胞接合平台開發的,"心切CEO唐仁宏博士說。"我們很高興與艾伯維合作這一新藥候選,期待共同推動SIM0500的臨牀開發。"

Simcere Zaiming will receive an upfront payment from AbbVie and is eligible to receive option fees and milestone payments of up to $1.055B, as well as tiered royalties on net sales outside of the Greater China territory. AbbVie is eligible to receive tiered royalties on net sales in the Greater China territory

心切將從艾伯維獲得預付款,並有資格獲得高達10.55億美元的選擇費和里程碑付款,以及在大中華區以外的淨銷售分級版稅。艾伯維在大中華區的淨銷售中有資格獲得分級版稅。

About AbbVie in Oncology

在艾伯維,我們致力於爲難治性癌症患者改變治療標準。我們正在推進一系列腫瘤類型的研究性治療藥物,包括血液腫瘤和實體腫瘤。我們致力於創建靶向治療腫瘤細胞繁殖或使其消除的靶向藥物。我們通過各種靶向治療模式來達成這一目標,包括抗體藥物偶聯物(ADCs)、免疫腫瘤學以及雙特異性和CAR-T平台。我們的專業團隊與創新合作伙伴聯手加速潛在的突破性治療藥物的推出。

At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and in situ CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

在艾伯維公司,我們致力於改善難治性癌症患者的護理標準。我們正在推動一系列癌症類型的研究治療pipeline,包括血液癌症和實體腫瘤。我們的重點是創造針對性的藥物,這些藥物要麼阻礙癌細胞的繁殖,要麼促使其消除。我們通過各種靶向治療方式和生物干預實現這一目標,包括小分子藥物、抗體藥物偶聯物(ADCs)、免疫腫瘤治療藥物、多特異性抗體和原位CAR-t平台。我們專注和經驗豐富的團隊與創新合作伙伴攜手合作,加速潛在突破性藥物的交付。

Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit .

今天,我們廣泛的腫瘤學產品組合包括了針對各種血液和實體腫瘤的批准和試驗性治療。我們正在評估20多種實驗性藥物,參與多個臨牀試驗,針對一些世界上最普遍和最具毀滅性的癌症。在努力對人們的生活產生顯著影響的同時,我們致力於探索幫助患者獲得癌症藥物的解決方案。欲了解更多信息,請訪問。

About AbbVie

關於艾伯維公司

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. AbbVie strives to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in AbbVie's Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

艾伯維的使命是發現並提供創新藥物和解決方案,以解決當前嚴重的健康問題並應對未來的醫療挑戰。艾伯維致力於對人們的生活產生顯著影響,涵蓋多個關鍵治療領域——免疫學、腫瘤學、神經科學和眼科——以及艾伯維的艾爾根美學產品組合中的產品和服務。欲了解有關艾伯維的更多信息,請訪問我們的網站。關注@abbvie,了解更多在LinkedIn、Facebook、Instagram、X(前Twitter)和YouTube上的動態。

About Simcere Zaiming

關於Simcere Zaiming

Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, "Simcere"). Founded in 2023, Simcere Zaiming dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in China, including COSELA, Enweida, Endostar, and Enlituo. The company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners.

Simcere Zaiming是一家專注於腫瘤學的生物製藥公司,是信立泰製藥集團有限公司(香港交易所:2096,"信立泰")的子公司。Simcere Zaiming成立於2023年,致力於開發突破性的治療方案,以滿足全球癌症患者未被滿足的臨牀需求。憑藉強大且創新的研發pipeline,擁有獨特的臨牀資產,Simcere Zaiming在中國成功推出了多款創新產品,包括COSELA、恩維達、恩多星和恩利托。該公司決心通過內部研發、製造和商業化能力,並與領先合作伙伴的戰略合作,向全球癌症患者提供可能具有變革性的治療選擇。

SOURCE Simcere Zaiming

來源:信立佳 宰明

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想讓貴公司的資訊在PRNEWSWIRE.COM上特色展示嗎?

440k+
440k+

Newsrooms &
新聞編輯室和

Influencers
意見領袖
9k+
9k+

Digital Media
數字媒體

Outlets
Outlets
270k+
270k+

Journalists
記者

Opted In
已選擇加入
GET STARTED
開始

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 350

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。